Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oradoxel Dose Regimen-Finding Study in Advanced Malignancies
NCT02963168Phase 1Unknown
- Sponsor
- Athenex
- Start
- Apr 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Oradoxel in solid tumor (advanced stage), sponsored by Athenex. Primary endpoint: Maximum Tolerated Dose at 3 weeks. Status: unknown.
02
Drugs
Oradoxel
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02963168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02963168.